After allogeneic bone marrow transplantation (BMT), the beneficial graft-versus-leukemia (GVL) effect but also the life-threatening graft-versus-host disease (GVHD) are mediated by Τ cells of the grafted marrow The Identification of leukemia cell-reactive Τ cells and their ligands are, therefore, crucial for the development of new anti leukemia strategies. Here we describe a leukemia-reactive allo-HLA class II restricted CD4 + T-cell clone, 6.2, isolated from a healthy individual after Stimulation with allogeneic leukemic cells. Clone 6 2 recognizes leukemic cells from several AML patients without showing reactivity to unfractioned peripheral blood mononuclear cells, monocytes, Β cells, T-cell blasts, and proximal tubulus epithelial cells. Interestingly, clone 6.2 A LLOGENEIC bone marrow transplantation (BMT) is the therapy of choice for the treatment of several hematologic malignancies, such as leukemia ' Today the occuirence of graft-versus-host disease (GVHD) remains a major comphcation of the BMT 2 5 In the current view, both GVHD and graft versus leukemia (GVL) effects of the BMT are mediated by donor denved mature Τ cells Deplction of Τ cells from the BM effectively prevents GVHD, but lesults in a high rate of leukemia relapses 6 8 Furtheimoie, patients with relapsed chronic myeloid leukemia can be effectively treated by admimstration of donor lymphocytes 9 Several clmical tnals show a direct association between GVL and GVHD and suggest that the GVL effect may be the reflection of the antihost reactivity against leukemic cells and is, there fore, not separable from GVHD 410 " On the othei hand, recent analyses of a large number of patients in the International Bone Marrow Tiansplantation Register point out that GVL can be observed independent of senous GVHD 12 Also, results from expenmental munne modeis suggest that GVL and GVHD can be mediated by separate as well as by ldentical T-cell populations n 16 These data have been also supported by some recent studies in humans where T-cell lmes and clones could be isolated, and these preferentially recogmzed leukemic cells 17 22 These in vitro studies, together with the clmical data, suggest that leukemia-associated antigens must exist Ne\ ertheless, in most cases the isolated Τ cells appeared not solely leukemia specific or difficult to mamtam in vitro I8 21 In our search for Τ cells that are reactive with leukemiaassociated antigens, we have investigated the in vitro T-cell response of a healthy mdividual against the leukemic cells of an HLA class II mismatched unrelated AML patient with AML Ml classification We have isolated several T-cell clones, of which the majonty was directed against subtle HLA class II diffeiences between the responder and the stimulator One CD4 + prohferative and cytotoxic T-cell clone recognized only leukemic cells from several AML patients in an allo-HLA-DR restricted fashion This T-cell clone also recognized HLA class II matched BM cells Neither CD34~, more differentiated precursors m the BM nor mononuclear cells in the peripheral blood (PB) are recognized by Τ cell clone 6 2, suggesting that lts target antigen is also recognizes BM cells derived from healthy individuals and inhibits the colony formation of myeloid and erythroid cell lineages. In the BM, clone 6.2 recognizes only CD34 + early precursor cells but not CD34 , more differentiated cells. Thus, the target antigen of clone 6.2 is developmentally regulated and expressed only by leukemic cells and CD34
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+ early progenitor cells in the hematopoietic System. We suggest that targeting the T-cell immune response to leukemia-associated, developmentally regulated antigens of the hematopoietic System can provide a basis for the Separation of GVL from GVHD, and may lead to new therapeutic approaches for residual and relapsed leukemia. © 1997 by The American Society of Hematology.
MUTIS ET AL
PBMCs from six random donors The EBV-transformed Β cells were further expanded in RPMI + 10% FCS
Phytohemagglutinin (PHA) Blasts
PBMCs were cultured in the presence of 0 1 ^g/niL PHA for 3 days Activated T-cell blasts (PHA blasts) were further expanded for three days using recombinant interleukin-2 (rIL-2) (20 U/mL) containing culture medium
Generation of Leukemia-Reactive T-Cell Lines and Clones
Stimulator cells Leukemic cells of an AML paüent with AML-Ml subclassification were used as stimulator cells The HLA typmg of the leukemic cells was HLA-A3,-B7,-B62,-Cw7,-DR13(DRBl*1302),-DR15(DRBl*1501), -DR52(Dw26)(-DRB3*0301), -DQw6(DQB 1*0602, *0604), -DPB1*0301,*0601
Responder cells PBMCs of a healthy individual were used as responder cells The HLA typing of the responder cells was HLA-A3,-B7,-B62,-Cw7,-DR13(DRBl*130I),-DR15(DRB 1*1501), -DR52(Dw25)(-DRB3*0202), -DQw6(DQBl*0602,*0603/07), -DPB1*0401,*0402
Before the mduction of pnmary T-cell cultures, stimulator Jeukemic cells were cultured for 72 hours with a cocktaü of cytokines consisting of 800 U/mL granulocyte-macrophage colony-stimulating factor (GM-CSF, tandly provided by Dr Osanto, Leiden, The Netherlands), 1,000 U/mL IL-4 (Genzyme, Leuven, Belgium), and 150 U/ raL tumor necrosis factor-a (TNF-α, Genzyme), in RPMI supplemented with 10% FCS, and antibiotics (penicilhn 100 U/mL, streptomycin 100 /ig/mL) Α total of 10 7 cytokine-treated, irradiated (30 Gy) leukemic cells were cocultured with 10 7 responder cells in 5 mL of culture medium (RPMI supplemented with 15% human serum [HS] and antibioücs), at 37°C, and 5% CO 2 On day 6 20 U/mL of rIL-2 was added in the culture On day 8 the T-cell line was restimulated with irradiated leukemic cells On day 15 the T-cell line was cloned by hmiüng diluüon at 0 3 cells/well in 96-well round-bottom microtiter plates in the presence of a feeder cell mixture containing irradiated PBMCs (30 Gy) from six random donors (1 Χ 10 6 cells/ mL), irradiated leukemic cells (30 Gy) (2 5 Χ 10 5 c/mL), 20 U/mL rIL-2, and 1% Leucoagglutimn-A (Sigma, St Louis, MO) rIL-2, 20 U/mL, was added to the cultures every 72 hours The T-cell clones were expanded by weekly restimulations with the above-descnbed feeder cell-cytokine mixture and tested for leukemia-specific cytotoxic and prohferative activities T-cell prohferatwn assays One to 2 Χ 10 4 responder Τ cells were cocultured with irradiated stimulator cells (2 to 10 Χ 10 4 c/ well) in 96-well flat-bottom microtiter plates dunng 88 hours Sixteen hours before harvesting the cultures were labeled with 0 5 μθ of 3 H-thymidine The 3 H-thymidine incorporation was determined by liquid scintillation counting The results are expressed as the mean of duphcate or tnplicate cultures The SEM of the results never exceeded 15%
Cytotoxwity assays 51 Cr-labeled target cells (3,000/well) were incubated with senal dilutions of effector Τ cells in 96-well roundbottomed microtiter plates (Costar 3799, Cambridge, MA) After 4 hours of incubation at 37°C, cell-free supernatants were obtained for gamma counting The percent specific Iysis was calculated as folIows % Specinc Lysis = (Expenmental Release -Spontaneous Release)/(Maximal Release -Spontaneous Release) X 100% Spontaneous release and the maximal release are the chromium release of target cells in culture medium alone and in cullure medium containing 1% Tnton-X 100 (Fluka, Buchs, Switzerland), respectivcly
To use as target cells, proximal tubulus epithelium cells (PTEC) were trypsinated and seeded at 3,000 c/well in 96-well flat-bottom microtiter plates After allowing adherence, TNF-a (150 U/mL) and interferon-γ (IFN -γ) (200 U/mL) were added to the wells to induce the HLA class II expression PTEC were cultured in the presence of cytokines for 72 hours Twelve hours before the assay 51 Cr (3 μθ/well) was added to the wells After washing, 5l Cr labeled, adherent PTEC were used as target cells in cytotoxicity assays
Hematopowtic precursor cell (HPC) growth Inhibition assays HPC growth Inhibition assays were performed as described previously 23 Bnefly, 125 Χ 10 5 bone marrow mononuclear cells (BMMNC) was mixed with effector Τ cells at different Τ ΒΜ cell ratios in 0 2 mL of HPC culture medium (Iscove's modified Dulbecco's medium [IMDM] supplemented with 30% plasma, 0 5 % bovine serum albumin [BSA], 0 47 g/L transfernn, 5 X 10 5 mol/L mercaploethanol, and 10% culture supernatant of Τ ceils) The cells were then either immediately resuspended to a final volume of 1 4 mL with semisohd HPC medium supplemented with 10 ng/mL rGM-CSF, 50 ng/mL rIL-3 (both from Sandoz, Basel, Switzerland), 2 IU r-erythropoieün (Cilag AG Int, Zug, Switzerland), and 1 3% methyl cellulose, or bnefly centnfuged (1,000g, 15 seconds) to establish BM-T-cell contact and incubated for 4 hours at 37°C in 5% CO 2 before transferring to the semisohd medium One milhliter of the semisohd suspension was plated in 30-mm plastic dishes and incubated at 37°C in 5% CO 2 After 14 days the number of erythrocyte burst-forming umts (BFU-E), colony-forming umt-granulocyles (CFU-G), and CFUmonocytes ( 
RESULTS

In Vitro Generation of Leukemw Reachve T-Cell Lines and Clones
The PBMCs of a healthy individual were used to generate in vitro T-cell responses agatnst leukemic cells of an unrelated AML patient The responder mdividual and the patient were serologically HLA identical, but showed subtle differences in HLA-DR, -DP, and -DQ genotypings (see Materials and Methods). Before using as stimulator cells, the leukemic cells were cultured with GM-CSF, IL-4, and TNF-α dunng 72 hours to increase their antigen-presenting capacity. The generated T-cell line showed prohferative and cytotoxic activity against leukemic cells at day 8 (data not shown) Several T-cell clones denved from this T-cell line were tested against leukemic cells, patient's EBV-BLCL, and HLAtyped PBMCs from healthy individuals. Based on the reaction patterns, four types of T-cell clones could be di&tin-guished (Fig 1) (1) The type I T-cell clones (n = 25) were reactive agatnst both leukemic cells and EBV-BLCL Thus, these clones were not able to discnminate leukemic from nonleukemic cells (2) The type II T-cell clones (n = 7) were reactive only to EBV-BLCL, suggesting that EBVassociated antigens were recogmzed. (3) The type III T-cell clones (n = 19) were reactive against leukemic cells but did not show reactivity against patient's EBV-BLCL, suggesting that their target antigen(s) were present on leukemic cells but not on nonleukemic EBV-BLCL However, when these T-cell clones were tested against a panel of PBMCs, which expressed the mismatched HLA class II antigens of the patient, all T-cell clones recogmzed one of more PBMCs Thus, type III T-cell clones were not directed against leukemiaassociated antigens, but most piobably to alloantigens that were expressed by PBMCs but not by EBV-BLCL (Fig 1B) Furthermore, clone 6 2 did not show reactivity against a psnel of PBMCs that shared HLA-class II antigens with leukf rnic cells (Fig 1B) These results indicated that Tcell clore 6 2 was not directed against antigens expressed by PBMCs, monocytes, or Β cells but reacted to an antigen that u, expressed only by leukemic cells.
T-Cell Clone 6 2 Is Restncted Via the Mio HLA-DRw26 Molecule
As shown in Fig 2A, the proliferative activity of the clone 6 2 agdinst leukemic cells was completely blocked by MoAb + monocytes from patient no 2 were obtained from PBMC by FACS sorting. EBV-BLCL and PHA blasts were also tested after culturing with GM-CSF (800 U/mL) + TNF-a (50 U/mL) + IL-4 (500 U/mL) for 72 hours. The thymidine uptake of T-cell clone 6 2 alone and the stimulator cells alone did not exceed 500 cpm. 
T-Cell Clone 6 2 Proliferates Against Other HLA-Dw26-Positive AML Cells Without Showmg Reactivity to Nonleukemic Cells
The T-cell clone 6 2 was subsequently tested against a panel of leukemic and nonleukemic cells denved from different leukemia patients (Fig 2B, left panel) Α CD4
+ alloreactive T-cell clone specific for the HLA-Dw26 molecule was used as control ( Fig 2B, nght panel) Beside lts reactivity dgdinst the original stimuldtor leukemic cells of the AMLMl patient (no. 1) (Figs 1B and 2A), clone 6 2 recognized two other leukemic cells from AML patients (nos 2 and 3) (Fig 2B, left panel) These leukemic cells were also recognized by the control HLA-Dw26 reactive T-cell clone ( Fig  2B, nght panel) , confirming the expression of HLA-Dw26 on the cell surface Note that the prohferative activity of both clone 6 2 and HLA-Dw26 specific dlloreactive T-cell clone against the leukemic cells of patient no 2 were blocked by antibody 7 3 19 1, lllustrating the HLA-Dw26 dependency of the recogmtion Leukemic cells from six HLADw26-negdtive AML or acute lymphobldstoid leukemia (ALL) patients were not recognized either by clone 6 2 or by the control HLA-Dw26-specific T-cell clone (Fig 2B) The leukemic cell-specific reactivity of clone 6 2 IS further demonstrated by absence of proliferation against different nonleukemic cell types obtained from patients no 2 and 3 Figure 2B shows that clone 6 2 did not recognize the EBV-BLCL and monocytes denved from patient no 2, clone 6 2 also failed to recognize PHA blasts or PBMCs denved from the HLA-identical BM donors of patients no 2 and 3 The EBV-BLCL and PHA blasts that were treated with GM-CSF/TNF-a/IL-4 Cocktail were also not stimulatory, mdicatmg that the target antigen of clone 6 2 was not induced on BLCL or Τ cells by these cytokines All tested HLA-Dw26-positive nonleukemic cells, including those that were treated with cytokines, were recognized by the control Dw26-reactive T-cell clone (Fig 2B, nght panel) , showmg that all assayed nonleukemic cells expressed the restncüon molecule and were capable of stimulatmg Τ cells (Fig 2B, nght panel) 
T-Cell Clone 6 2 Is Cytotoxic to Leukemic Bul Not to Nonleukemic Cells
T-cell clone 6 2 not only possessed prohferative activity against leukemic cells but also efficiently lysed the leukemic cells (Fig 3) Similar to lts prohferative activity, the cytotoxic activity of clone 6.2 was confined to leukemic cells Nonleukemic cells such as PHA blasts or EBV-BLCL denved from the patients no 1 and 2 or from their HLA-identical BM donors were not lysed (Fig 3) . BLCL or PHA blasts that were treated with the GM-CSF/TNF/IL-4 Cocktail were also not lysed (Fig 3) To assess whether nonhematopoietic cells can express the target antigen of clone 6 2, an HLA-DRB3*0301 -positive PTEC hne was tested as target cell (Fig 3) Clone 6.2 and a control dlloreactive T-cell hne that is directed to HLA-DRB1*13O2 and HLA-DRB3*0301 allo-determinants were used as effector cells Because PTECs do not constitutively express HLA class II, they were eultured with 200 U/mL IFN-γ + 150 U/mL TNF-α during 72 hours to induce HLA class II expression The control dlloreactive T-cell hne showed a nonsignificant lysis against untreated PTEC which lacked HLA-cldss II The mduction of HLA class II expression by IFN-γ and TNF-α led to the recogmtion of the PTEC by the control alloreactive T-cell line only, suggesting that the PTEC did not expressed the target antigen of clone 6.2.
T-Cell Clone 6 2 Recognizes CD34 + Hematopoielic Progenitor Cells and Inhibits the Growth of Erythroid, Monocytic, and Granulocytic Cell Lineages
T-cell clone 6.2 was tested against a panel of BM cells derived from healthy individuals (Fig 4A, left panel) . Likewise, the control HLA-Dw26-specific alloreactive T-cell clone, clone 6.2, recognized all HLA-Dw26-positive BM cells but did not recognize HLA-Dw26-negative BM cells (Fig 4A) . The proliferation of clone 6.2 against BM cells was inhibited by the antibody 7.3.19.1, confirming its HLA-DR-restricted reactivity (Fig 4B) . As expected, the PBMC derived from the HLA-Dw26-positive BM donors were not recognized (Fig 4B) . These results suggested that the clone 6.2 might recognize a developmentally regulated antigen that is expressed only by early progenitor cells present in the BM. To address this assumption, several FACS sorted BM cell populations were tested for their capacity to stimulate T-cell clone 6.2 (Fig 4C) . T-cell clone 6.2 recognized the unsorted BM cells, CD34
+ early progenitor cells, CD34 + , CD33 + early myeloid cell precursors, but not CD34" cells, including CD34~~, CD14 + monocytic lineage and CD34", CD15 + granulocytic cell lineage. These results indicated that the target antigen recognized by the antileukemic T-cell clone 6.2 was expressed by CD34 + BM early progenitor cells but not by more differentiated cells, including PBMCs. Note that the control HLA-Dw26-specific alloreactive Tcell clone recognized all cell subsets, indicating that the unresponsiveness of clone 6.2 to CD34" cells was not caused by a lack of stimulatory capacity ( Fig 4C, right panel) .
Because T-cell clone 6.2 displays cytotoxic activity, we addressed the question of whether it could also lyse BM cells and inhibit the outgrowth of different hematopoietic cell lineages. Therefore, we used BM cells as target cells in cytotoxicity assays (Fig 5) and in parallel we performed HPC growth Inhibition assays (Fig 6) . Α CD8 + HLA-A2-specific CTL clone was used as control.
T-cell clone 6.2 showed specific cytolysis against two HLA-Dw26-positive, unfractionated BM cells. As expected, HLA-Dw26-negative BM cells were not lysed ( Fig  5, left panel) . The moderate levels of lysis observed against these unfractionated BM cells was not surprising because clone 6.2 was expected to recognize only CD34 + cells in the BM. The control HLA-A2-specific CD8 + alloreactive T-cell clone significantly lysed the BM cells that were HLA-A2-positive (Fig 5, right panel) .
In HPC growth Inhibition assays (Fig 6) , clone 6.2 strongly inhibited the outgrowth of BFU-E, CFU-G, and CFU-M from two HLA-Dw26-positive BM (BM no. 1 and BM no. 2) at T:BM ratios as low as 0.3:1. HLA-Dw26-negative BM (BM no. 10, BM no. 11) were not inhibited, showing that the HPC Inhibition was specific and dependent on antigen presentation by BM cells. Likewise, the control HLA-A2-specific CTL inhibited the HPC growth from only HLA-A2-positive BMs no. 1, 10, and 11. Both clone 6.2 and alloreactive T-cell clone inhibited the number of the growing colonies, and no difference in the size of the colonies was observed, suggesting that the further outgrowth of the colonies was not inhibited. Furthermore, neither clone 6.2 nor the CD8 + alloreactive clone inhibited the HPC growth when the Τ cells and the BM cells were only mixed immediately before plating in the semisolid culture medium (data not shown), indicating that the Inhibition of HPC growth was dependent to cell-cell contact. These results were similar to those obtained by other CD8
+ CTL directed to alloantigens or to minor histocompatibility antigens. precursor cells However, other mechamsms such as mduction of apoptosis via fas-fasL mteractions cannot be excluded
DISCUSSION
After an allogeneic BMT mature Τ cells present in the graft inoculum appear to play d major role in the ehmination of residual leukemic cells 6 9 The understanding of the nature of the T-cell response directed to leukemic cells and the Identification of leukemia-associated T-cell antigens IS the basis of new therapeutic methods against leukemia This lssue was the mam focus of the present study
Over the past few years Η became clear that the proper activation of naive T-cell precursors m pnmary in vitro cultures requires efficient antigen presentation supported by strong costimulatory Signals dehvered by the antigen presenting cell (APC) 27 In this respect, leukemic cells may not function as proper APC since they usually lack or weakly express costimulatory molecules such as B7 1 and B7 2 This may be the reason why in some studies antileukemic T-cell lines and clones were reported to be functionally or physically unstable in culture Therefore, we decided to culture leukemic cells with GM-CSF, IL-4, and TNF-α These cytokines, which are known to generate adequate APC from monocytes, 2830 also increased the antigen-presenting capaclty of acute myeloid leukemia cells (manuscript in preparation)
Usmg this strategy, we investigated pnmary T-cell responses induced against allogeneic leukemic cells Beside T-cell clones that were reactive to leukemic cells and patient's EBV-BLCL, we have isolated other alloreactive Tcell clones that recognized leukemic cells, HLA-matched, allogeneic PBMCs, but not patient's EBV-BLCL (Fig 1A, type III clones) These latter T-cell clones are probably directed to allo-HLA determinants, which are apparently absent on EBV-BLCL More mterestmgly, we have isolated a T-cell clone, designated as "6 2," recogmzing an antigen present on vanous leukemic cells but absent on nonleukemic cells isolated from the PB, and on the kidney-denved PTEC This CD4 + T-cell clone appeared to recogmze lts target antigen not in a selfrestncted but in an allo HLA-DR-restncted fashion In this respect our results are in agreement with previous studies of Sosman et al, 17 18 who also have shown that allogeneic Τ cells can display specific antileukemic activity m vitro Similar to the Τ cells descnbed by Sosman et al, the antileukemic Tcell clone 6 2 descnbed here is CD4 + , class II restncted, and not only prohferates but also displays cytotoxic activity against leukemic cells Thus, lt is plausible that GVL effect after BMT can be mediated also by antileukemic CD4 + Τ cells Some recent studies indeed suggest that CD4 + Τ cells can mediate GVL effects without the apparent inducüon of GVHD 31 Moreover, in a recent clmical tnal, the GVL effect of the bufty coat transfusion was preserved by the depletion So far httle is known about the nature of the leukermaassociated antigens that tngger T-cell immune responses Several investigators consider leukemia-specific fusion proteins, such as the charactenstic BCR-ABL fusion protein in chronic myeloid leukemia (CML), as potential candidates for targeting the T-cell immune response specifically to leukemic cells 33 Although Τ cell responses can be generated against the BCR-ABL fusion peptides, lt has not been con vincmgly shown that BCR-ABL fusion product is naturally expressed in the context of HLA rnolecules In acute leukemids a vanety of turnoi-specific chromosome abnormalities occur Although the fusion products of these chromosomal translocations can be also considered as target antigens for the development of leukemia specific therapies, not a laige percentage of patients can be cured by such strategies because of the interindividual Variation in the chromosomal abnormalities However, several of these divers chromosomal translocations led to the activation of common transcnption factors that are important in differentiation 34 As yet lt is not known whether these developmcntally regulated antigens could tngger T-cell immune responses and seive as leukemia-associated T-cell antigens Our current results suggest that possibly such developmentally regulated antigens can be recognized by Τ cells The HLA-DR restncted T-cell clone 6 2 descnbed here specifically recognizes leukemic cells from several AML patients and reacts to CD34 + BM cells without showing reactivity against CD34 BM cells or against nonleukemic cells denved from PBMC The target antigen of clone 6 2 is also not present on a nonhematopoietic system-denved cell line PTEC Although we weie not able to test other somatic tissue cells, and thus lt still remams possible that an othei cell type can be recognized, so far clone 6 2 shows a very limited target cell specificity m the hematopoietic System The most hkely explanation of this specific target cell specificity is that clone 6 2 recognizes a developmentally regulated antigen of the hematopoietic System, which is involved in the differentiation of early pro genitor cells This antigen is also expressed on leukemic cells that are arrested in an early stage of the differentiation Because the Τ cell clone effectively inhibits the outgrowth of hematopoietic precursor cells and lyses the leukemic cells, the use of this clone for the treatment of leukemia after BMT may result in ehmination of lesidual leukemic cells in the PB and their precursors in the BM without the nsk of GVHD The mam cnticism against such a therapeutic approach is that the T-cell clone 0 2 will also lecognize grafted BM and presumably will not allow the outgrowth of several cell lineages This nsk can be avoided by transplantation of an HLA-Dw26-neg<itive, thus a one allele HLA DR mismatched Β Μ graft, because the T-cell clone 6 2 will recognize lts target antigen only in the context of HLA-Dw26 lt is obvious that in such a transplantation setting the BM graft should be T-cell depleted to avoid the nsks of senous GVHD and the rejection of the CTL clone Alternatively, furmshmg the T-cell clone 6 2 with a suicide gene, such as Hsv-tk gene, may allow the control of the T-cell clone in vivo belore BMT In conclusion, our results suggest that targeting the Τ cell immune response to the developmentally regulated antigens of the hematopoietic System may be possible, and lead to new approaches in the leukemia treatment
